The Myeloma Crowd Research Initiative (MCRI) successfully raised $500,000 for two immunotherapy research projects for high-risk myeloma (CAR T and T cell treatments). Now, the MCRI will fund research to match the right treatment with the right patient at the right time.
A small fraction of multiple myeloma patients may already be cured but researchers don’t know who, how and why. Some patients can live years without relapse while others struggle with aggressive high-risk myeloma and die quickly. Patients relapse or become refractory to treatments because the disease changes over time and with each treatment. Each myeloma case is an ever-moving target.
Being able to tell prospectively which drugs may, or may not work, in a given patient will help to ensure that patients are receiving the best personally relevant treatment while avoiding any unnecessary treatment. Because most therapies are being given as doublets, triplets or quad therapies, it is increasingly more important to understand the personal relevance to the tumor, the bone marrow microenvironment and the patient’s immune system.
The MCRI taps into the power of crowdsourcing to find and fund the best ideas, research and clinical applications leading to the best treatments to achieve longer lives and potential cures.
We are crowdsourcing to find the best ideas, tests and research to ensure that the correct drug or drug combination will work in each individual myeloma patient before it is administered, giving patients more effective treatments, longer life and a potential cure.
Learn more about the MCRI process below and help us bring curative treatments to all myeloma patients by donating today.Donate Today
Research Proposal Submissions
Research proposals are now being accepted for Myeloma Crowd Research Initiative funding that help myeloma specialists, hematologists and oncologists provide the optimal treatment to an individual myeloma patient. This could include biomarker discovery, pharmacogenetics, or predictive medicine tests, procedures or research. The proposals will be reviewed based on the proposed idea, cost, investigator experience, relevance to the individualized patient (including a patient’s immune system status, myeloma genetics and bone marrow microenvironment), absence of commercial funding, concrete milestones and time to clinic.
Two to four projects will be selected. Grant amounts will be based on the project type, need and available funding.
The research project must utilize and integrate with HealthTree, a software product that helps myeloma patients find their best treatment options.
Two-Page Summary Submission Deadline: March 30, 2018
Proposal Review and Acceptance Timeline
- March 31, 2018: Submission deadline for 2-page description
- April 1 – May 15: Myeloma Crowd Scientific Advisory Board Review
- May 15: Short List Projects Selected and notified
- May 15 – June 30: Full proposal submissions
- July 1 – August 30: Proposal reviews and final selections
- September 1: Final selections notified